 |
4’-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2’-(ethoxymethyl)-[1,1’-biphenyl]-2-sulfonamide |
|---|---|
| Trade Name | |
| Orphan Indication | Focal segmental glomerulosclerosis |
| EU Market Approval | EU |
| EU Designation Date | 2015-11-11 00:00:00 |
| Sponsor | Retrophin Europe Limited |
